Consistent high prevalence of undiagnosed blood-borne virus infection in patients attending large urban emergency departments in England. by Hopkins, Mark J et al.
J Viral Hepat. 2019;00:1–4.	 	 	 | 	1wileyonlinelibrary.com/journal/jvh
1  | INTRODUC TION
Innovative care pathways including case finding and linkage to care 
are crucial to achieve the World Health Organization targets for 
the elimination of viral hepatitis.1 In England, there were over 23.4 
million attendances at Emergency departments (EDs) in 2016‐2017 
representing a significant opportunity to engage for case finding.2 
EDs may be the only healthcare access point for some marginalized 
groups including recent migrants, homeless or people who inject 
drugs. Seroprevalence studies have been used in the USA to guide 
public health interventions where large scale, integrated ED test‐
ing and linkage programs are increasingly common.3 Since 2008, 
routine opt‐out testing for HIV in UK ED settings has been recom‐
mended for those in high prevalence areas (>0.2%). However, similar 
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Abstract
Understanding local viral hepatitis and HIV epidemiology is essential if WHO elimi‐
nation targets are to be achieved. We demonstrate a consistently high prevalence of 
undiagnosed active infection in urban emergency department attendees in England, 
with variations in local risk groups crucial to informing targeted testing initiatives.
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recommendations for hepatitis B virus (HBV) and hepatitis C virus 
(HCV) have not been produced given a lack of UK evidence to sup‐
port routine testing in this setting.4
The aim of this study was to estimate undiagnosed BBV prev‐
alence in three urban EDs in different areas of England to inform 
testing strategies.
2  | METHODS
Standardized unlinked anonymous BBV prevalence surveys were 
conducted using residual biochemistry blood from ED attendees 
at three sites in England: two London hospitals in the southeast of 
England (Charing Cross (CXH) and St Mary's (SMH)) and one city in 
the northwest of England (Liverpool). Unselected deduplicated lists 
of	ED	U&E	blood	samples	for	inclusion	in	the	study	were	generated	
using laboratory information systems. Inclusion criteria were (a) age 
16‐65	years	 and	 (b)	 ≥0.75	mL	 surplus	 serum	 in	 the	primary	blood	
tube. Previously diagnosed BBV prevalence in this cohort was esti‐
mated through interrogation of local health care IT records to report 
the aggregate number of diagnosed infections. Individual routine 
pathology results were not retained. Samples were then irreversibly 
anonymized except for sex, age and ethnicity prior to screening for 
hepatitis B surface antigen (HBsAg), HCV antibody and HIV anti‐
gen/antibody. Positive results were confirmed using neutralization, 
RNA and lineblot assays. Active infection was defined as HBsAg that 
was either neutralizable or confirmed on a second assay, HCV RNA 
≥15	IU/mL,	HIV	antigen/antibody	confirmed	with	two	different	im‐
munoassays or HIV‐1 RNA. All testing was undertaken in accredited 
NHS laboratories in accordance with ISO 15189. Proportions were 
calculated amongst all samples with known results. Undiagnosed 
BBV was estimated by subtracting previously diagnosed from sur‐
vey‐diagnosed prevalence. Crude risk ratios for overall infection (as 
defined by positive study result) were calculated using Stata 15 for 
each BBV by sex, age and ethnicity. The study was approved by the 
NHS Research Ethics Service (reference 17/LO/0255, 17/SW/0096).
3  | RESULTS
4574 samples from unique ED attendees between May 2017 and 
August 2017 were tested: CXH n = 1500; SMH n = 1500; Liverpool 
n = 1574. 46.3% of samples were from male patients. Median age 
was 41 (IQR 29‐53) years. Ethnicity was recorded for 3541 (77.4%) 
attendees, of whom 1680 (47.4%) self‐identified as white British. 
The study population is described in greater detail in the supporting 
information (Table S1).
Overall active BBV infection prevalence in the total study popu‐
lation was 3.3% (95% confidence interval [CI] 2.8%‐3.8%). Of these, 
101/150 (67.3%) were undiagnosed according to local databases 
F I G U R E  1   Prevalence of previously known and undiagnosed active blood‐borne virus infection in unselected ED attendees in England 
stratified by infection and location. A total of 4574 unique patient samples were tested at three sites: two London hospitals (Charing Cross; 
n = 1500 and St Mary's; n = 1500) in the southeast of England and one city in the northwest of England (Liverpool; n = 1574). Undiagnosed 
prevalence calculated using local health records. Previous exposure to HCV infection defined by detection of HCV antibody. HCV active 
infection defined by detection of HCV RNA. BBV, blood‐borne virus; ED, emergency department
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giving an undiagnosed BBV prevalence of 2.2% (range across the 
three sites 1.1%‐3.3%).
Active infection prevalence for each virus was HCV 1.5% 
(range 0.7%‐2.7%), HBV 1.1% (range 0.4%‐2.0%) and HIV 0.8% 
(range 0.1%‐1.5%), with corresponding undiagnosed prevalence 
of HCV 0.7% (0.5%‐1.0%), HBV 0.8% (0.1‐1.7%) and HIV 0.8% 
(0.1%‐1.3%). There were 7 co‐infections (0.1%). Whilst overall ac‐
tive BBV infection prevalence was broadly similar across sites (CXH 
2.7% [CI 1.9%‐3.6%], SMH 4.0% [CI 3.1%‐5.1%], Liverpool 3.2% 
[CI 2.4%‐4.2%]), variation was seen in local BBV prevalence pat‐
terns (Figure 1). For example, active HCV infection accounted for 
86% of local BBV infections in Liverpool (HCV prevalence 2.7% [CI 
2.0%‐3.7%]), compared with 25% in London (HCV prevalence 1.0% 
[CI 0.6%‐1.6%] and 0.7% [CI 0.3%‐1.2%] at CXH and SMH, respec‐
tively). Conversely, HBV and HIV infections were more common in 
London: HBV 0.9% (CI 0.5%‐1.6%), HIV 1.0% (CI 0.6%‐1.7%) at CXH; 
HBV 2.0% (CI 1.4%‐2.8%), HIV 1.5% (CI 0.9%‐2.2%) at SMH com‐
pared with HBV 0.4% (CI 0.2%‐0.9%), HIV 0.1% (CI 0.0%‐0.4%) in 
Liverpool.
All infections were more common in males than females (5.3% 
vs 1.5%). This increased risk was greatest for HIV (risk ratio [RR] of 
5.1 [CI 2.3‐11.7], P < .001), followed by HCV (RR 4.5 [CI 2.5‐8.0], 
P < .001)), but males also had twice the risk of HBV (RR 2.1 
[CI1.2‐3.7], P = .008). Highest prevalence was consistently in the 
36‐45 age group (HCV 3.0%, HBV 1.9%, HIV 1.6%) with risk ratios 
of 2.2 [CI1.2‐4.1] for HCV P = .013, 2.8 [CI1.0‐7.6] for HBV P = .045, 
5.9 [CI 1.3‐26.0] for HIV P < .019 compared with the risk in those 
aged 16‐25.
A disproportionately high prevalence of all BBV infection was 
found in people of black ethnicities in ethnically diverse London; 
6.1% of 115 Black Caribbean attendees had a BBV infection (4.4% 
HCV, 0.9% HBV, 0.9% HIV) and 9.6% of 136 Black African attendees 
(0.0% HCV, 6.6% HBV, 3.7% HIV). In contrast, most infections (0.3% 
HBV, 2.3% HCV, 0.0% HIV) in Liverpool were amongst white British.
4  | DISCUSSION
To our knowledge, this study is the largest multicentre anonymous 
BBV data set from UK ED attendees. We demonstrate a consist‐
ently high active BBV prevalence at all urban ED sites (3.3% [range 
2.7%‐4.0%]), and the results confirm those of an earlier HCV study 
adding weight to the case for systematic BBV testing in this popula‐
tion.5 Of particular importance given existing public health objec‐
tives was that two thirds of active infections were estimated to be 
locally undiagnosed.
Our overall HIV prevalence findings are in line with those re‐
ported in previous UK studies, although the proportion of previously 
undiagnosed infections was higher (0.8% vs 0.3%).6 This may reflect 
the limitation of using local databases for prior diagnosis but also 
local demographic variation or chance.
National BBV surveillance is coordinated through Public Health 
England with ED data accounting for a small proportion of this 
surveillance. Estimated prevalence figures in 2015 were HCV anti‐
body 2.2%, HBsAg 1.2% and HIV Ag/Ab 1.4%. The 2015 surveillance 
does not report if these are previously diagnosed and/or engaged 
with care. Using this data and modelling estimates the general popu‐
lation prevalence of active HCV infection in England is estimated at 
0.4%.7 In contrast to this, we demonstrated nearly fourfold higher 
HCV RNA prevalence in ED attendees overall, increasing to seven‐
fold in Liverpool, and estimated the proportion of new cases without 
previous diagnosis.
Also our estimate of undiagnosed HBV infection (0.8%) suggests 
inclusion of EDs within HBV elimination strategies will allow case 
finding in populations not covered by targeted testing initiatives 
or existing HBV screening such as the infectious diseases in preg‐
nancy. Commissioners are encouraged to develop locally enhanced 
services for hepatitis B and C in areas where there is a higher than 
average number of people at increased risk; however, developing 
policies beyond risk‐based testing in ED is hampered by a lack of 
robust local epidemiological data.4 There is significant opportunity 
within EDs to identify new cases of viral hepatitis through increased 
testing with subsequent linkage to treatment and immunization ini‐
tiatives: the EDs involved in this study engaged with 352 618 at‐
tendees in 2016‐2017, of which half can be expected to have bloods 
taken, but as yet none of these EDs currently employ systematic 
BBV testing.8 Our results support the case to implement system‐
atic BBV testing in urban ED attendees triaged for a blood draw, 
although we recommend other regions undertake prior assessment 
of local prevalence to inform if a selective testing policy may be 
appropriate.
Laboratory BBV test tariffs vary considerably between providers 
in the UK. When including resolution of false positives and using 
averaged standard tariffs, laboratory costs per active diagnosis in 
our study were £663 HCV, £563 HBV and £1277 HIV (Table S2). 
Laboratory assay cost will have a key impact on high‐volume ED 
testing. However, savings are likely achievable through price‐volume 
and test bundle agreements. Further work is underway to estimate 
cost‐effectiveness of systematic testing in the English EDs.9 Testing 
in this area is not without challenge given the high pressure on staff 
time and potential costs involved. However, there is substantial US 
and emerging UK evidence of the effectiveness of electronic patient 
record (EPR) triggered ED BBV screening programmes and that sub‐
sequent engagement with the care cascade can be effective and sus‐
tainable.3,8 Molecular platforms now facilitate near‐patient nucleic 
acid testing, and results can be available within NHS ED waiting time 
targets.10 Coupled with improved therapy options, the environment 
now exists for new pathways to be considered for increased diagno‐
sis and rapid linkage to care.
Our study has a number of limitations. Our study used routinely 
collected ED data and was not designed to collect clinical data or other 
risk factors such as homelessness or injecting drug use. Further, our 
data pertain to populations triaged for a blood draw which may dif‐
fer from low‐risk patients attending for minor injuries.10 Conversely, 
the requirement for surplus serum might add a bias against patients 
with poor venous access such as PWID, although this would have led 
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to our results representing an underestimate. The anonymous study 
model relied on local healthcare databases for known prevalence 
estimates, so prior diagnosis in another healthcare service using dif‐
ferent laboratories cannot be excluded. However, we feel this would 
apply less to the undiagnosed prevalence in the more unitary health‐
care economies outside London. Importantly, prior diagnosis does 
not equate to engagement with care which is especially relevant for 
HCV and marginalized populations in general. Testing in the ED pro‐
vides an opportunity to re‐diagnose and re‐engage for treatment. 
Whilst our aim was primarily to inform viral hepatitis ED epidemiol‐
ogy, and our site sample size therefore sufficiently powered for HCV 
and HBV, we acknowledge it was likely underpowered to precisely 
estimate HIV prevalence.
Our multicentre results support emerging evidence that urban 
ED BBV testing initiatives could provide a valuable contribution 
to improve diagnosis and linkage to care pathways in England. We 
recommend that testing strategies are informed by local prevalence 
data if WHO targets are to be achieved.
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